Next Generation Probiotics (NGPs) are live microorganisms identified through advanced techniques like next-generation sequencing and bioinformatics, which, when administered in adequate amounts, confer specific health benefits to the host. Unlike traditional probiotics, such as Lactobacillus and Bifidobacterium, which are often isolated from fermented foods and have broad, non-specific effects, emerging NGPs are typically isolated from the human gut microbiota, making them better adapted to the intestinal environment. They are designed for targeted therapeutic applications, addressing specific diseases like inflammatory bowel disease, obesity, diabetes, cancer, and neurodegenerative disorders.
At present, there are a number of promising NGP strains, like Akkermansia muciniphila, Faecalibacterium prausnitzii and Bacteroides fragilis, being identified and studied, demonstrating potential in modulating gut microbiota, enhancing immunity, and producing beneficial metabolites. However, NGPs face challenges like oxygen sensitivity, stringent regulatory requirements, and the need for advanced delivery systems to ensure viability and efficacy.
Traditional probiotics focus on survival, abundance, and general balance, primarily using traditional food-derived strains with broad, non-specific functions.
Next-Generation Probiotics (NGPs) go beyond presence and quantity. They are function-defined, mechanism-driven, and clinically translated, selected based on specific biological activities, host interaction, and measurable outcomes.
This marks a shift from “more bacteria” to “right biology” — precision modulation instead of population replacement.
| Generation | Definition | Key Features | Typical Applications |
|---|---|---|---|
| Traditional Probiotics | Classic gut-beneficial bacteria Common strains -Lactobacillus, Bifidobacterium |
General health, gut health |
General health supplements, food and beverages |
| Next Gen Probiotics – NGPs | Human microbiome-isolated functional strains | Precise mechanisms; strong metabolic & immune effects | Potential applications in targeted effects in disease management or precision supplement |
REVIVEBIO’s proprietary flagship strain, Parabacteroides goldsteinii RV-01 (P. Gold RV-01), is a NGP extensively researched over the past 15 years, exhibiting remarkable potentials in the areas of anti-aging, metabolism enhancement, anti-neuroinflammation and immunity modulation. P. Gold RV-01 has been evaluated for its toxicity, functionality, mechanism, efficacy and safety.
Beyond its scientific merit, P. Gold RV-01 represents a highly strategic commercial asset. Its long-term research foundation, combined with well-established safety and mechanistic validation—including GRAS self-affirmation—significantly lowers regulatory and commercialization barriers, enabling faster market entry and scalable global deployment.
